Silke Hedtfeld

Mrs. Silke Hedtfeld


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in BMC Genomic Data
Verified
Journal Article
Open access
NCNikoletta Charizopoulou
Nikoletta Charizopoulou
SHSilke Hedtfeld
Silke Hedtfeld
MDMartina Dorsch
Martina Dorsch
FSFrauke Stanke
Frauke Stanke
JDJulia R Dorin
Julia R Dorin
BTBurkhard Tümmler
Burkhard Tümmler
A major boost to the cystic fibrosis disease research was given by the generation of various mouse models using gene targeting in embryonal stem cells. Moreover, the introduction of the same mutation on different inbred strains generating congenic strains facilitated the search for modifier genes. From the original CftrTgH(neoim)HguCF mouse model we have generated using strict brother × sister mating two inbred CftrTgH(neoim)Hgumouse lines (CF/1 and CF/3). Thereafter, the insertional mutation was introgressed from CF/3 into three inbred backgrounds (C57BL/6, BALB/c, DBA/2J) generating congenic animals. In every backcross cycle germline transmission of the insertional mutation was monitored by direct probing the insertion via Southern RFLP. In order to bypass this time consuming procedure we devised an alternative PCR based protocol whereby mouse strains are differentiated at the Cftr locus by Cftr intragenic microsatellite genotypes that are tightly linked to the disrupted locus. Using this method we were able to identify animals carrying the insertional mutation based upon the differential haplotypic backgrounds of the three inbred strains and the mutant CftrTgH(neoim)Hguat the Cftr locus. Moreover, this method facilitated the identification of the precise vector excision from the disrupted Cftr locus in two out of 57 typed animals. This reversion to wild type status took place without any loss of sequence revealing the instability of insertional mutations during the production of congenic animals. We present intragenic microsatellite markers as a tool for fast and efficient identification of the introgressed locus of interest in the recipient strain during congenic animal breeding. Moreover, the same genotyping method allowed the identification of a vector excision event, posing questions on the stability of insertional mutations in mice.

1 May 2017 in Journal of Biotechnology
Verified
Journal Article
Closed access
LWLutz Wiehlmann
Lutz Wiehlmann
KPKatarzyna Pienkowska
Katarzyna Pienkowska
SHSilke Hedtfeld
Silke Hedtfeld
MDMarie Dorda
Marie Dorda
BTBurkhard Tümmler
Burkhard Tümmler

9 April 2008 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
BTBalázs Tóth
Balázs Tóth
MWMartina Wilke
Martina Wilke
Frauke StankeFrauke Stanke
Frauke Stanke
MDMartina Dorsch
Martina Dorsch
SHSilke Hedtfeld
Silke Hedtfeld
BTBurkhard Tümmler
Burkhard Tümmler
Background: A major boost to cystic fibrosis disease research was given by the generation of various mouse models using gene targeting in embryonal stem cells. Moreover, the introduction of the same mutation on different inbred strains generating congenic strains facilitated the search for modifier genes. From the original Cftr TgH(neoim)Hgu mouse model with a divergent genetic background (129/Sv, C57BL/6, HsdOla:MF1) two inbred mutant mouse strains CF/1-Cftr TgH(neoim)Hgu and CF/3-Cftr TgH(neoim)Hgu had been generated using strict brother × sister mating. CF/1-Cftr TgH(neoim)Hgu and CF/3-Cftr TgH(neoim)Hgu mice were fertile and showed normal growth and lifespan. In this work the Cftr TgH(neoim)Hgu insertional mutation was backcrossed from CF/3-Cftr TgH(neoim)Hgu onto the inbred backgrounds C57BL/6J and DBA/2J generating congenic animals in order to clarify the differential impact of the Cftr mutation and the genetic background on the disease phenotype of the cystic fibrosis mutant mice. Clinical and electrophysiological features of the two congenic strains were compared with those of CF/1-Cftr TgH(neoim)Hgu and CF/3-Cftr TgH(neoim)Hgu and wild type controls. Results: Under the standardized housing conditions of the animal facility, the four mouse strains CF/1-Cftr TgH(neoim)Hgu , CF/3-Cftr TgH(neoim)Hgu , D2.129P2(CF/3)-Cftr TgH(neoim)Hgu and B6.129P2(CF/3)-Cftr TgH(neoim)Hgu exhibited normal life expectancy. Growth of congenic cystic fibrosis mice was comparable with that of wild type controls. All mice but D2.129P2(CF/3)-Cftr TgH(neoim)Hgu females were fertile. Short circuit current measurements revealed characteristic response profiles of the HsdOla:MF1, DBA/2J and C57BL/6J backgrounds in nose, ileum and colon. All cystic fibrosis mouse lines showed the disease-typical hyperresponsiveness to amiloride in the respiratory epithelium. The mean chloride secretory responses to carbachol or forskolin were 15–100% of those of the cognate wild type control animals. Conclusion: The amelioration of the clinical features and of the basic defect that had emerged during the generation of CF/3-Cftr TgH(neoim)Hgu mice was retained in the congenic mice indicating that the Cftr linkage group or other loci shared between the inbred strains contain(s) the major modifier(s) of attenuation of cystic fibrosis symptoms.

Verified
Journal Article
Open access
PDF file
ASAlexander Schnell
Alexander Schnell
STStephanie Tamm
Stephanie Tamm
SHSilke Hedtfeld
Silke Hedtfeld
CGClaudio Rodriguez Gonzalez
Claudio Rodriguez Gonzalez
AHAndre Hörning
Andre Hörning
AMAntje Munder
Antje Munder
The Cystic Fibrosis Conductance Transmembrane Regulator gene encodes for the CFTR ion channel, which is responsible for the transport of chloride and bicarbonate across the plasma membrane. Mutations in the gene result in impaired ion transport, subsequently leading to perturbed secretion in all exocrine glands and, therefore, the multi-organ disease cystic fibrosis (CF). In recent years, several studies have reported on CFTR expression in immune cells as demonstrated by immunofluorescence, flow cytometry, and immunoblotting. However, these data are mainly restricted to single-cell populations and show significant variation depending on the methodology used. Here, we investigated CFTR transcription and protein expression using standardized protocols in a comprehensive panel of immune cells. Methods: We applied a high-resolution Western blot protocol using a combination of highly specific monoclonal CFTR antibodies that have been optimized for the detection of CFTR in epithelial cells and healthy primary immune cell subpopulations sorted by flow cytometry and used immortalized cell lines as controls. The specificity of CFTR protein detection was controlled by peptide competition and enzymatic Peptide-N-Glycosidase-F (PNGase) digest. CFTR transcripts were analyzed using quantitative real-time PCR and normalized to the level of epithelial T84 cells as a reference. Results: CFTR mRNA expression could be shown for primary CD4+ T cells, NK cells, as well as differentiated THP-1 and Jurkat T cells. In contrast, we failed to detect CFTR transcripts for CD14+ monocytes and undifferentiated THP-1 cells, as well as for B cells and CD8+ T cells. Prominent immunoreactive bands were detectable by immunoblotting with the combination of four CFTR antibodies targeting different epitopes of the CFTR protein. However, in biosamples of non-epithelial origin, these CFTR-like protein bands could be unmasked as false positives through peptide competition or PNGase digest, meaning that the observed mRNA transcripts were not necessarily translated into CFTR proteins, which could be detected via immunoblotting. Our results confirm that mRNA expression in immune cells is many times lower than in that cells of epithelial origin. The immunoreactive signals in immune cells turned out to be false positives, and may be provoked by the presence of a high-affinity protein with a similar epitope. Non-specific binding (e.g., Fab-interaction with glycosyl branches) might also contribute to false positive signals. Our findings highlight the necessity of accurate controls, such as CFTR-negative cells, as well as peptide competition and glycolytic digest in order to identify genuine CFTR protein by immunoblotting. Our data suggest, furthermore, that CFTR protein expression data from techniques such as histology, for which the absence of a molecular weight or other independent control prevents the unmasking of false positive immunoreactive signals, must be interpreted carefully as well.

29 September 2021 in Genes
Verified
Journal Article
Open access
PDF file
Frauke StankeFrauke Stanke
Frauke Stanke
TBTim Becker
Tim Becker
HIHaide Susanne Ismer
Haide Susanne Ismer
IDInga Dunsche
Inga Dunsche
SHSilke Hedtfeld
Silke Hedtfeld
BTBurkhard Tümmler
Burkhard Tümmler
CFTR encodes for a chloride and bicarbonate channel expressed at the apical membrane of polarized epithelial cells. Transepithelial sodium transport mediated by the amiloride-sensitive sodium channel ENaC is thought to contribute to the manifestation of CF disease. Thus, ENaC is a therapeutic target in CF and a valid cystic fibrosis modifier gene. We have characterized SCNN1B as a genetic modifier in the three independent patient cohorts of F508del-CFTR homozygotes. We could identify a regulatory element at SCNN1B to the genomic segment rs168748-rs2303153-rs4968000 by fine-mapping (Pbest = 0.0177), consistently observing the risk allele rs2303153-C and the contrasting benign allele rs2303153-G in all three patient cohorts. Furthermore, our results show that expression levels of SCNN1B are associated with rs2303153 genotype in intestinal epithelia (p = 0.003). Our data confirm that the well-established biological role of SCNN1B can be recognized by an association study on informative endophenotypes in the rare disease cystic fibrosis and calls attention to reproducible results in association studies obtained from small, albeit carefully characterized patient populations.

Verified
Journal Article
Open access
PDF file
STStephanie Tamm
Stephanie Tamm
RDRebecca Dalferth
Rebecca Dalferth
LFLonghua Feng
Longhua Feng
MKMark-Christian Klassen
Mark-Christian Klassen
SHSilke Hedtfeld
Silke Hedtfeld
Frauke StankeFrauke Stanke
Frauke Stanke
Background/Objectives: Primary airway epithelia grown at air–liquid interface (ALI) are widely used to model respiratory endophenotypes and to enable individualized functional testing. However, culture conditions used to establish ALI vary considerably and may introduce selection biases. We aimed to adapt our lung explant-based ALI protocol to nasal basal cells obtained by minimally invasive brushing and to identify expansion conditions that optimize the number of primary epithelia that can be generated from nasal brushing while preserving donor-specific features. Methods: Primary nasal basal cells from nine healthy adult donors were expanded using different protocol variations in a paired design. We systematically varied two factors during the expansion phase: (a) supplementation with Rho-associated kinase (ROCK) and SMAD pathway inhibitors and (b) a single passage prior to ALI differentiation. Outcomes included the likelihood of obtaining a well-formed, differentiated ALI epithelium and functional readouts relevant to respiratory phenotyping. Results: The probability of establishing a well-differentiated ALI epithelium in a single attempt was highest when expansion was performed without ROCK/SMAD inhibitors and without passaging. Among successfully established ALI cultures, replicate inserts from the same donor showed comparable CFTR expression and ciliary beat frequency; however, functional chloride secretion could only be robustly detected in a subset of epithelia and was associated with low epithelial apoptosis. Conclusions: Avoiding strong selection pressures during the expansion phase—by omitting ROCK/SMAD inhibitors and minimizing passaging—improves the success rate of obtaining well-differentiating primary nasal ALI cultures and likely preserves cellular diversity among founder cells of the epithelium. These findings support the use of patient-derived nasal ALI cultures as robust, reproducible platforms for individualized respiratory phenotyping and functional assessment in personalized medicine.